secnidazole

Trade name: solosec

Small moleculeapprovedFast Track FDA

Approved

Sep 15, 2017

Secnidazole (trade names Flagentyl, Sindose, Solosec) is a nitroimidazole derivative used to in the treatment of amoebiasis and bacterial vaginosis. Secnidazole and other 5-nitroimidazole drugs enter micro-organisms by passive diffusion and undergo activation by reduction of the 5-nitro group. In anaerobic micro-organisms, such as Trichomonas, Giardia and Entamoeba spp., this intracellular reduction occurs via the pyruvate ferredoxin oxidoreductase complex and results in a concentration gradient across the cell membrane which, in tum, enhances transport of the parent drug into the cell. Because the electron affinity of the 5-nitroimidazoles is greater than that of reduced ferredoxin, the drug interrupts the normal electron flow. Aerobic micro-organisms have a more positive redox potential (i.e. are more efficient electron acceptors) than secnidazole and other 5-nitroimidazoles, which explains the selective toxicity of these drugs against anaerobic microorganisms. DNA is the intracellular target of the Secnidazole and other 5-nitroimidazoles. Secnidazole and other 5-nitroimidazoles possess selective activity against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In general, secnidazole and metronidazole were approximately equipotent in activity against Bacteroides fragilis, Trichomonas vaginalis, and Entamoeba histolytica, in in vitro studies. Secnidazole is rapidly and completely absorbed after oral administration. Plasma drug concentrations are linear over the therapeutic dose range of 0.5 to 2g. The tolerability profile of secnidazole does not differ markedly from other 5-nitroimidazoles. The most commonly reported adverse events in clinical trials involved the gastrointestinal tract (nausea, vomiting, glossitis, anorexia, epigastric pain and a metallic taste) and occurred in 2 to 10% of patients. A headache and dizziness were experienced by about 2% of patients. The drug was equally well tolerated in adults and children, and no adverse event required therapeutic intervention or treatment withdrawal. — NCATS

Clinical trial activity

11 trials · 12 clinical orgs · 3 marketing orgs

Phase 1
1
Phase 2
7
Phase 3
6
Phase 4
2

Earliest trial started Jun 1, 2003 (NCT00607074)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2014

    Symbiomix Therapeutics — Earliest Phase 2 Sponsor(trial)

  3. Sep 15, 2017

    Symbiomix Therapeutics — Earliest FDA Approval

  4. Sep 15, 2017

    Lupin — NDA Secondary Org

  5. Sep 15, 2017

    Symbiomix Therapeutics — NDA Organization

  6. Sep 15, 2017

    Evofem Inc. — Marketing Organization

Indications

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

    Enters bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis

Approval history

  • approvedPriority reviewFast trackSep 15, 2017

Chemistry & pharmacology

Loading structure…

SMILES

CC(O)CN1C(C)=NC=C1[N+]([O-])=O
Mol. weight
185.1805 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(2­ hydroxypropyl)-2-methyl-5-nitroimidazole
  • 1-(2­ hydroxypropyl)-2-methyl-5-nitroimidazole
  • 1-(2'-hydroxypropyl)-2-methyl-5- nitroimidazole
  • 1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2­ ol
  • 1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2­ ol
  • 14,539 rp
  • flagentyl
  • minovag
  • pm-185184
  • pm-185184
  • rp-14539
  • rp-14539
  • sabima
  • secnidal
  • secnidazol
  • secnidazol
  • secnidazol
  • secnidazol
  • secnidazole
  • secnidazole
  • secnidazole
  • secnidazole
  • secnidazole
  • secnidazole
  • secnidazole
  • secnidazole
  • secnol
  • seknidazol
  • sym-1219
  • sym-1219
  • sym-1219

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06261840Phase 4Jul 1, 2024Louisiana State University, Tulane University, University of Alabama, Birmingham
NCT05033743Phase 2/Phase 3 (Phase 3)Jul 9, 2021Indiana University, Lupin
NCT03935217Phase 3Apr 23, 2019Lupin
NCT03937869Phase 4Nov 12, 2018Lupin
NCT02452866Phase 3Jun 1, 2015Symbiomix Therapeutics
NCT02418845Phase 3May 1, 2015Symbiomix Therapeutics
NCT02147899Phase 2May 1, 2014Symbiomix Therapeutics
NCT02111629Phase 3May 1, 2012Universidad Nacional de Colombia
NCT01733966Phase 3May 1, 2010Laboratoires Iprad, QuantaBio
NCT01019083Phase 1/Phase 2 (Phase 2)Feb 1, 2008International Center for Diarrheal Disease Research, University of Gothenburg
NCT00607074N/AJun 1, 2003University of Cambridge
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
LupinFor profit3222018
Symbiomix TherapeuticsFor profit3322014
Indiana UniversityAcademic/Hospital1112021
International Center for Diarrheal Disease ResearchAcademic/Hospital1112008
Laboratoires IpradFor profit1012010
Louisiana State UniversityAcademic/Hospital1012024
QuantaBioFor profit1112010
Tulane UniversityAcademic/Hospital1112024
Universidad Nacional de ColombiaAcademic/Hospital1112012
University of Alabama, BirminghamAcademic/Hospital1012024
University of CambridgeAcademic/Hospital1112003
University of GothenburgAcademic/Hospital1012008
12 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
Evofem Inc.For profitMKTGSep 15, 2017
LupinFor profitNDA2Sep 15, 2017
Symbiomix TherapeuticsFor profitNDASep 15, 2017